The phase 2 study's results are certainly unprecedented in MS. But whether Campath (alemtuzumab), a monoclonal antibody (mAb) already approved to treat leukemia, actually 'reverses' MS ...

There is growing clinical evidence that aHSCT can treat RRMS more effectively than DMTs. However, as most data is registry-based and previous trials did not directly compare aHSCT with the most ...